Abstract 4540
Background
Introduction of PH (2012) and K (2013) in the US changed the standard-of-care for HER2-positive mBC. RW studies reported decreased K effectiveness in pts with PH pre-tx. We studied whether timing of PH and K availability in clinical practice could introduce selection bias (i.e. pts with K after PH in early yrs of availability may have to have had rapid progression during PH tx to be included in RW analyses).
Methods
Using de-identified data from the US-based Flatiron electronic health record-derived database, we selected pts diagnosed with mBC on/after 1 Jan 2011 and initiating K between 1 Feb 2013 and 31 Jul 2018. Primary analysis included all pts receiving K (any tx line). Subgroup analysis focused on pts with 2nd-line K tx after PH tx. Time from index date to next tx/death (TTNT) was used as a proxy for progression-free survival.
Results
Primary cohort (N = 533) demographics were generally consistent across yrs (2013–18); median age was 61 yrs; 89% had prior HER2-targeted tx; 23% had brain metastases (mets); 68% had visceral mets. In pts with (n = 231) vs without (n = 79) prior PH, median age was 61 vs 65 yrs, mean time from mBC diagnosis was 16 vs 18 months, 27% vs 20% had brain mets, 74% vs 58% had visceral mets. Additional findings are shown (Table). Prevalence of prior PH exposure almost doubled over the yrs. In 2nd-line K treated pts with prior PH, time from mBC to K increased over the yrs, paralleled by a numerical increase in median TTNT.Table:
356P
2013 | 2014 | 2015 | 2016 | 2017 | 2018 | |
---|---|---|---|---|---|---|
Primary cohort (N = 533) | ||||||
N | 51 | 77 | 108 | 106 | 117 | 74 |
Prior PH, n (%) | 18 (35.3%) | 35 (45.5%) | 72 (66.7%) | 80 (75.5%) | 77 (65.8%) | 53 (71.6%) |
TTNT, median months (95% CI) | 6.8 (4.9–14.2) | 6.5 (4.2–9.2) | 7.6 (4.7–9.8) | 6.3 (5.1–8.4) | 8.4 (6.4–10.3) | Data not yet mature |
% Censored | 13.7% | 10.4% | 9.3% | 17.0% | 36.8% | |
Subgroup analysis (N = 231) | ||||||
Pts with 2nd-line K use after PH, N | 13 | 25 | 56 | 51 | 52 | 34 |
mBC to K initiation in pts with 2nd-line K use after PH, mean months (SD) | 12.7 (6.9) | 13.1 (8.5) | 13.0 (8.0) | 16.0 (12.9) | 17.9 (12.5) | 18.6 (11.6) |
TTNT in pts with 2nd-line K use after PH, median months (95% CI) | 5.1 (3.0–7.5) | 7.2 (4.6–11.7) | 6.6 (4.5–8.4) | 10.3 (5.6–12.8) | Data not yet mature | |
% Censored | 7.9% | 8.9% | 15.7% | 40.4% |
CI, confidence internal; SD, standard deviation.
Conclusions
Prevalence of PH pre-tx increased, yet K effectiveness remained consistent across yrs. With PH launched shortly before K, the initial pts receiving K were possibly selected due to shorter benefit from prior PH. This selection bias may explain reports of lower K effectiveness in pts with prior PH tx. This illustrates the challenges of assessing tx sequence effectiveness shortly after tx approval.
Clinical trial identification
Editorial acknowledgement
Writing assistance was provided by Meredith Kalish, MD, of Ashfield Healthcare Communications (a UDG Healthcare plc company), and funded by F. Hoffmann-La Roche Ltd.
Legal entity responsible for the study
F. Hoffmann-La Roche Ltd.
Funding
F. Hoffmann-La Roche Ltd.
Disclosure
T. Sanglier: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. C. Flores: Full / Part-time employment: Genesis Research. E. Flahavan: Shareholder / Stockholder / Stock options: Eli Lilly; Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. N. Lindegger: Honoraria (self), Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche; Shareholder / Stockholder / Stock options: Novartis; Shareholder / Stockholder / Stock options: Idorsia; Shareholder / Stockholder / Stock options: J&J. F. Montemurro: Speaker Bureau / Expert testimony: Novartis; Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: Ely Lilly; Speaker Bureau / Expert testimony: Pfizer; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
4331 - STING Agonist, ADU-S100, Yields Potent Antitumor Activity and Therapeutically Favorable Immune Profile in an Esophageal Adenocarcinoma Model
Presenter: Ali Zaidi
Session: Poster Display session 2
Resources:
Abstract
1770 - Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract
3755 - A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: a GISCAD trial.
Presenter: Roberto Labianca
Session: Poster Display session 2
Resources:
Abstract
2439 - The analysis of T cell subsets and clinical efficacy of immune checkpoint blockades in patients with advanced gastric cancer using multiplex immunohistochemistry
Presenter: Tae-yong Kim
Session: Poster Display session 2
Resources:
Abstract
2211 - First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma.
Presenter: Yelena Janjigian
Session: Poster Display session 2
Resources:
Abstract
3046 - Monitoring patient-specific mutation in ctDNA and CTC for tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric cancer (NCT03425058)
Presenter: Tao Fu
Session: Poster Display session 2
Resources:
Abstract
4628 - Gastric cancer screening in BRCA 2 gene mutation carriers: should it be recommended?
Presenter: Inês Oliveira
Session: Poster Display session 2
Resources:
Abstract
2127 - Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)
Presenter: Yu Sunakawa
Session: Poster Display session 2
Resources:
Abstract
2264 - Prediction of S-1 adjuvant chemotherapy efficacy in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis
Presenter: Masanori Terashima
Session: Poster Display session 2
Resources:
Abstract
2444 - Assessing the clinical utility of circulating tumour DNA through longitudinal liquid biopsy sampling in Oesophageal adenocarcinoma
Presenter: Emma Ococks
Session: Poster Display session 2
Resources:
Abstract